The CALGB/SWOG 80405 study reported no significant difference in overall survival and progression-free survival when patients with KRAS wild-type metastatic CRC were treated with bevacizumab or cetuximab, both in combination with leucovorin/fluorouracil/oxaliplatin (FOLFOX) or leucovorin/fluorouracil/irinotecan (FOLFIRI) [23]. Here, KRAS is linked to colorectal carcinoma.